Module1_Home_banner
This content is intended for healthcare professionals only

Module 1

Recognising when
people with hay fever
are struggling


Up to 2 in 3 people with hay fever have moderate-to-severe symptoms1 that are bothersome enough to reduce quality of life.2-4

Signs someone is struggling with bothersome symptoms include disruption to the following:3

• Sleep    • Daily tasks
• Outdoor activities     • Work

Be the one to help them find fast, effective relief

Many hay fever sufferers frequently experience severe symptoms while taking treatment.4

Almost 3 in 4 people

with hay fever use multiple medicines, often at the same time.4,5

Many become trapped in a cycle of insufficient relief,4,5

using 3 or more medicines before speaking to a pharmacist.3



You can make a difference.

7 in 10 people follow their pharmacist’s advice on hay fever products.4

Dymista® CONTROL can break their cycle of insufficient relief.

More effective at reducing all EYE and NOSE symptoms of hay fever than a steroid spray alone (FP)6 or in combination with oral antihitamine (LORA).7

 

  • Disruption to sleep, daily tasks, outdoor activities and work are signs someone has moderate-to-severe hay fever.3
  • Using multiple medicines, often at the same time, could be a sign someone is stuck in a cycle of insufficient hay fever relief.4,5
  • You can make a difference. Your recommendation can help to break the cycle of insufficient relief.3

Module 1 summary

people
people

Module 2

Breaking the Struggle

Next Module

FP = fluticasone propionate; LORA = loratadine;

Click here for Product information

References

1. Canonica G, et al. Allergy. 2007;62(suppl 85):17–25. 2. Canonica G, et al. World Allergy Organ J. 2008;1(9):138–144. 3. Viatris. Dymista® CONTROL Consumer Research. December 2025. 4. Carr W, et al. J Allergy Clin Immunol. 2012;129(5):1282–1289.e10. 5. Pitman R, et al. Allergy. 2012;67(suppl 96):342–342. 6. Meltzer E, et al. Int Arch Allergy Immunol. 2013;161:369–377. 7. Bousquet J, et al. J Allergy Clin Immunol Pract. 2018;6(5):1726–1732.

UK-DTC-2026-00021 March 2026

X